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Role of duodenal lipid and cholecystokinin A
receptors in the pathophysiology of functional
dyspepsia
C Feinle, O Meier, B Otto, M D’Amato, M Fried
Abstract
Background/aims—We aimed to evaluate
the role of fat and cholecystokinin (CCK)
in the pathophysiology of functional dys-
pepsia (FD) by investigating symptoms
and plasma CCK levels following increas-
ing doses of duodenal lipid during gastric
distension, and the eVect of CCK-A
receptor blockade.
Subjects/methods—In study A, six FD
patients were studied on three occasions
during duodenal infusion of saline or lipid
(1.1 (L-1) or 2 kcal/min (L-2)) and proxi-
mal gastric distensions. Six healthy sub-
jects were also studied as controls during
L-2 only. In study B, the eVect of the
CCK-A antagonist dexloxiglumide (5 mg/
kg/h) on L-2 induced symptoms was stud-
ied in 12 FD patients. Changes in gastric
volume at minimal distending pressure
and plasma CCK (study A) were assessed,
gastric distensions were performed using
a barostat, and dyspeptic symptoms were
monitored.
Results—Lipid increased gastric volume
compared with saline (ÄV (ml): saline 15
(20), L-1 122 (42), L-2 114 (28)) in patients
and even more so in controls (221 (37);
p<0.05). During distensions, symptoms
were greater during L-2 than during
saline or L-1, and greater in patients than
in controls, while gastric compliance was
smaller in patients than in controls
(p<0.05). Lipid increased plasma CCK
levels in patients and controls (p>0.05).
Dexloxiglumide abolished the increase in
gastric volume (ÄV (ml): dexloxiglumide
17 (9), placebo 186 (49)) and dyspeptic
symptoms (sum of scores: dexloxiglumide
24 (7), placebo 44 (19)) during duodenal
lipid infusion. Dexloxiglumide also re-
duced gastric compliance (ml/mm Hg:
dexloxiglumide 51 (7), placebo 72 (11))
and symptoms (sum of scores: dexloxiglu-
mide 101 (17), placebo 154 (21)) during
gastric distension.
Conclusion—CCK-A receptors are in-
volved in the generation of dyspeptic
symptoms by duodenal lipid during gas-
tric distension.
(Gut 2001;48:347–355)
Keywords: functional dyspepsia; duodenal lipid;
cholecystokinin; dyspeptic symptoms
Many patients with functional dyspepsia ex-
hibit hypersensitivity of the stomach to
distension.1–3 Gastric distension is perceived as
painful at smaller intragastric volumes and
lower pressures compared with healthy sub-
jects. In addition to mechanical stimulation by
food, the gastrointestinal tract is also stimu-
lated chemically by nutrients. There is now
accumulating evidence that nutrients, particu-
larly foods containing fat, play an important
role in the generation of dyspeptic symptoms.4–6
We have previously shown that duodenal infu-
sion of lipid exacerbates the hypersensitivity to
distension in patients with functional dyspep-
sia. Moreover, combining gastric balloon dis-
tension with duodenal lipid infusion repro-
duced dyspeptic symptoms in these patients.7
This eVect appears to be specific for fat as
infusion of an isocaloric glucose solution into
the duodenum did not induce the same symp-
tomatic response.8 The specificity of this
response for fat suggests involvement of chole-
cystokinin (CCK), as CCK is released mainly
by the presence of fat in the small intestine.9
CCK is regarded as a satiety hormone10 and has
also been implicated in the induction of nausea
in healthy humans.11 In addition, we have pre-
viously found evidence for involvement of
CCK in lipid induced nausea in a study in
healthy subjects.12 The nausea experienced
during distension of the proximal stomach and
duodenal infusion of lipids was improved by
pretreatment with the CCK-A receptor an-
tagonist loxiglumide. Intravenous administra-
tion of CCK has been shown to reproduce
symptoms in patients with functional dyspep-
sia, and symptoms were relieved by oral
administration of loxiglumide.13 It is therefore
possible that CCK dependent mechanisms
underlie dyspeptic symptoms that occur in
response to fat ingestion.
The aim of this study was therefore to inves-
tigate the eVect of the CCK-A receptor
antagonist dexloxiglumide on symptom devel-
opment during duodenal lipid infusion and
gastric distension in patients with functional
dyspepsia, and to assess the eVect on patient
sensitivity to gastric distension. Specifically, we
wished to investigate the hypothesis that
duodenal lipid would induce symptoms in
patients with functional dyspepsia by releasing
CCK, and that these symptoms could be
alleviated using a CCK-A receptor antagonist.
In addition, we studied the relationship be-
tween increasing doses of duodenal lipid
during gastric distension, plasma CCK levels,
and severity of symptoms.
Abbreviations used in this paper: FD, functional
dyspepsia; CCK, cholecystokinin; MDP, minimal
distending pressure; VAS, visual analogue scale; AUC,
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Subjects and methods
SUBJECTS
Twelve patients (10 women, two men; aged
22–61 years) with functional dyspepsia (for
criteria see below) and six healthy subjects (five
women, one man; aged 23–49 years) were
included in the studies. All subjects were of
normal body weight for height (BMI: patients
21 (1) kg/m2; healthy subjects 20 (1) kg/m2),
non-smokers, and were not receiving any
medication during the course of the study. The
study was carried out with the approval of the
ethics committee at the University Hospital
Zürich. All subjects gave informed written
consent prior to participation.
Subjects with functional dyspepsia were
recruited from the staV and students of the
University of Zurich via an email describing the
symptomatic criteria required for entry into the
study. In a telephone interview, patients were
selected for further investigation depending on
the presence and severity of symptoms. Pa-
tients had at least three of the following symp-
toms for more than six months, of at least a
moderate severity: postprandial fullness/early
satiety, bloating, epigastric pain, and nausea/
vomiting. Severity was scored on a 0–3 scale
with 0 representing “symptoms not experi-
enced”, 1 “slight symptoms, but not trouble-
some”, 2 “moderate symptoms, troublesome,
but not impairing daily activities”, and 3
“severe symptoms, impairing daily activities”.
Patients who had previously undergone gastro-
intestinal surgery or were receiving medica-
tions that could not be discontinued for the
duration of the study were excluded from the
study.
Each patient underwent laboratory tests,
upper gastrointestinal endoscopy, ultrasound,
and a 13C urea breath test for determination of
Helicobacter pylori status. If all investigations
were negative, the patient was admitted into
the study. Healthy subjects had to have no his-
tory of gastrointestinal disease and no experi-
ence of any symptoms suggestive of dyspepsia.
Each subject was required to visit the labora-
tory once before the start of the study. During
this visit, subjects were familiarised with the
requirements of the study, the gastric (barostat)
tube, study procedures, and symptom ques-
tionnaires. Only two subjects, who were unable
to swallow the tubes, were excluded from the
study.
METHODS
Duodenal tube and infusions
To deliver duodenal infusions, a thin (OD 2.8
mm (8 FR), length 109 cm) flexible polyvinyl
tube (Merck Biomaterials, Alton, UK) was
inserted through the nose into the small intes-
tine. The tube was equipped with a side port
approximately 5 cm from its tip. The infusion
port was positioned approximately 15 cm distal
to the pylorus, and the correct position of the
tube was verified fluoroscopically. The follow-
ing solutions were used during the studies: iso-
tonic saline, 10% and 20% lipid emulsion
(Intralipid 10% and 20%; Pharmacia AG,
Dübendorf, Switzerland; 260 mosmol/kg; en-
ergy density 1.1 or 2 kcal/ml, respectively, con-
taining 10% or 20% fractionated soy bean oil,
respectively, 1.2 g fractionated egg phospholip-
ids, and 2.25 g glycerol). The solutions were
infused at a rate of 1 ml/min.
Gastric tube and barostat
Subjects swallowed a second highly flexible
single lumen tube (OD 3.5 mm, ID 2.8 mm;
Tygon Tubing, Upchurch Scientific, Oak Har-
bor, Washington, USA). To distend the proxi-
mal stomach, a flaccid thin walled polyethylene
bag (capacity 1100 ml) was attached to and
tightly wrapped around the distal end of the
tube. The bag was positioned in the fundus of
the stomach by distending it with air, carefully
pulling it back until its passage was restricted
by the lower oesophageal sphincter, and then
pushed back in again by 2 cm. In addition to
assisting in the unfolding and positioning of the
bag, this first distension also ensured reproduc-
ibility of the data obtained during all subse-
quent distensions carried out during the course
of the study. It has previously been demon-
strated that during a series of distensions, data
become reproducible from the second disten-
sion onwards.4 14 The proximal end of the tube
was connected via a three way tap to the
measurement and balloon ports of a gastric
barostat (Distender Series II, G&J Electronics
Inc., Willowdale, Ontario, Canada). The func-
tioning of the barostat has been described in
detail previously.15 In brief, it is capable of
monitoring changes in gastric volume at a fixed
pressure. Thus if the gastric wall relaxes, air is
injected into the gastric bag to maintain the
pressure, while air is withdrawn if the stomach
contracts. In addition, distensions of the stom-
ach can be carried out.
Blood sampling (study A)
Blood samples were obtained repeatedly
throughout the study (fig 1) to determine
plasma levels of CCK at baseline, every five
minutes during duodenal infusions, and at the
beginning and end of each distension. Samples
were collected into chilled EDTA tubes,
centrifuged at 2°C within 30 minutes of collec-
tion and stored at −70°C until extraction.
Plasma CCK was determined by a sensitive
and specific radioimmunoassay, as described
previously.16 The antibody used binds to all
biologically active CCK peptides containing
sulphated tyrosine with almost equal aYnity.
Sulphated gastrins cross reacted <1% in the
assay, while no cross reactivity was found with
unsulphated gastrins or CCK-8. The mean
detection limit of the assay was 0.3 (0.1) pmol/l
with a confidence limit of 95%. The coeY-
cients of variation were 5.6% at 0.67 pmol/l
and 7.2% at 15.1 pmol/l for intra-assay
variation, and 12.3% at 0.85 pmol/l and 15% at
14.8 pmol/l for interassay variation.
Intravenous infusion of the CCK-A receptor
antagonist dexloxiglumide (study B)
Either dexloxiglumide (Rotta Research Labo-
ratorium SpA, Monza (MI), Italy) or 0.9%
saline (placebo) was administered into a
forearm vein. Dexloxiglumide, the
(D−)enantiomer of loxiglumide, is responsible
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for the pharmacological activity of loxiglu-
mide.17 During the first 10 minutes of the
study, dexloxiglumide was infused at a rate of
15 mg/kg/h to reach equilibrium. Subse-
quently, the rate was reduced to 5 mg/kg/h for
the remainder of the study to maintain
adequate drug plasma levels throughout the
study ensuring complete and selective block-
ade of CCK-A receptors. The dose of dexlox-
iglumide used in the present study was based
on previous data using the related compound
loxiglumide. Loxiglumide is approximately half
as potent as dexloxiglumide but has been
shown to produce almost complete and
selective blockade of CCK-A receptors at a
dose of 10 mg/kg/h.18
EXPERIMENTAL PROTOCOL
All studies were carried out at least six days and
no more than 16 days apart, and each study
took approximately four hours. For study A,
examinations were performed at lunch time, at
least four hours after breakfast, and for study B
in the morning after an overnight fast. In study
A, patients were allowed a light breakfast con-
sisting of coVee or tea, two thin slices of bread,
butter, and jam. Thereafter, only water was
allowed up to one hour prior to the study. Once
the tubes and intravenous catheter were in
place, subjects were comfortably seated in an
upright position on a hospital bed and the
study protocol (fig 1) commenced. Initially, the
minimal distending pressure (MDP) was
determined by raising intrabag pressure with
the barostat in steps of 1 mm Hg/min. MDP
has previously been defined as the pressure that
is necessary to overcome intra-abdominal
pressure resulting in a bag volume of at least 30
ml. Intragastric pressure was set at MDP and
volume was monitored until a stable recording
was obtained for at least 10 minutes (baseline).
MDP prior to the start of any duodenal
infusion was 8 (1) mm Hg and did not diVer
between study days or between healthy subjects
and patients.
Study A: dose-response study
To determine the relationship between the
dose of lipid administered and severity of dys-
peptic symptoms, six patients were studied on
three occasions each. They received a duodenal
infusion of either isotonic saline, or 10% or
20% lipid in a randomised order following a
Latin square design. Patients were blinded as to
the nature of all infusions and the investigator
performing the studies was blinded as to which
lipid emulsion he had administered. Six healthy
subjects were studied during infusion of 20%
lipid only. During the lipid infusions, an energy
load of approximately 70 or 120 kcal (corre-
sponding to 1.1 or 2 kcal/min for 10% and 20%
lipid, respectively) was administered. An en-
ergy delivery of 2 kcal/min approximates the
normal gastric emptying rate, and the lower
dose was chosen to establish a dose-response
relationship. During infusions, changes in
proximal gastric tone (as changes in intrabag
volume) were assessed for 30 minutes. Then,
MDP was determined again, followed by two
isobaric distension periods separated by 15
minutes. MDP was not significantly lowered by
any of the infusions in patients but decreased to
6 (1) mm Hg after infusion of 20% lipid in
healthy subjects (p<0.05). For distensions,
1 mm Hg stepwise increases in intrabag
pressure (starting at the initially determined
MDP) were performed while volumes at the
diVerent pressure steps were monitored. Each
pressure level was maintained for one minute.
We chose a stepwise increasing (ramp) as
Figure 1 Experimental protocols for study A (dose-response study) and study B (cholecystokinin (CCK)-A receptor
blockade). To determine the relationship between the lipid dose administered and severity of dyspeptic symptoms, six patients
were studied on three occasions each, receiving duodenal infusion of 0.9% saline, or 10% or 20% lipid. Six healthy subjects
were studied after infusion of 20% lipid only. During infusions, changes in gastric volume were assessed and the proximal
stomach was distended in steps of 1 mm Hg/min while symptoms were monitored and plasma CCK levels determined. In
study B, 12 patients were studied twice to investigate the eVect of CCK-A receptor blockade with dexloxiglumide on the
symptomatic and gastric volume responses evoked by duodenal infusion of 20% lipid and gastric distension. VAS, visual
analogue scale.
Distension 1 Distension 230 min
15 min
10 min
Duodenal infusion of saline or lipid 10% or 20% (1 ml/min)




Distension 1 Distension 230 min
15 min
10 min10 min 10 min
Duodenal infusion of lipid 20% (1 ml/min)
Intravenous infusion of dexloxiglumide or placebo
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opposed to a random distension protocol for
three main reasons. Firstly, the ramp protocol
most closely mimics gastric distension during
food ingestion. Secondly, as patients were not
explicitly told that “their stomachs would be
distended” but were informed that during the
study gastric pressures and volumes would be
assessed or manipulated, subjects were not able
to anticipate when or that a distension was car-
ried out. Thirdly, we feared that randomly
exposing patients to painfully high distension
stimuli (as may be the case with random
distension protocols) might lead to anxiety and
hypervigilance resulting in a reduction in
sensory thresholds.19
Study B: CCK-A receptor blockade study
Twelve patients (including the six subjects
from study A) were studied on two occasions
each to investigate the eVect of CCK-A recep-
tor blockade on the symptomatic response to
duodenal infusion of 20% lipid and gastric dis-
tension. The study followed a double blind
placebo controlled design, and the two study
conditions were carried out in a randomised
order. Intravenous administration of the
CCK-A receptor antagonist dexloxiglumide or
placebo commenced immediately after the
baseline recording at a rate of 15 mg/kg/h for
10 minutes (equilibrium), was then reduced to
5 mg/kg/h for 10 minutes (steady state), and
continued at this rate for the duration of the
study. Duodenal infusion of lipid was then
started and the protocol followed as described
for study A.
ASSESSMENT OF SYMPTOMS
The severity of symptoms of fullness, bloating,
epigastric discomfort, pain, and nausea was
assessed at baseline and every 10 minutes dur-
ing duodenal infusions, and at the beginning
and the end of each distension on visual
analogue scales (VAS). In addition, during one
of the two distensions, symptoms were assessed
every minute at the end of each distension step
to obtain a continuous progression of symp-
toms with increasing distension. The VAS con-
sisted of a 10 cm line, with 0 cm representing
“sensation not present” and 10 cm “strongest
sensation ever felt”.20 Distensions were discon-
tinued as soon as the subjects rated any of the
sensations at “9” on the VAS, indicating severe
discomfort. A sum of symptoms score was
obtained for infusion and distension periods,
respectively, by adding scores obtained from all
symptoms over time in individual subjects.
This score was only used in the “abstract” to
summarise the diVerences between treatments.
To minimise the influence of visual or audi-
tory cues on perception data, the barostat
device and infusion pump were placed behind
the subject’s back, and the barostat was kept
running continuously (that is, even during
breaks in the protocol) to maintain a constant
level of noise. In addition, subjects were not
aware of the timing of any of the procedures.
For example, it was not specified when disten-
sions were carried out.
DATA ANALYSIS
Gastric volume changes
To evaluate changes in gastric volume during
the diVerent experimental conditions, the
volume readings obtained during the baseline
recording (10 minutes), during the 30 minutes
of duodenal lipid or saline infusions and, in
study B, additionally during the equilibrium
and steady state periods, were averaged, and
areas under the curves (AUC) were calculated.
Gastric distensions
During distensions, intragastric volumes dur-
ing consecutive pressure steps were calculated
by averaging the volume readings obtained
during the last 30 seconds of each pressure
step. These data were then used to construct
pressure-volume profiles. Any diVerences be-
tween the volume profiles obtained during gas-
tric distensions and the experimental condi-
tions in studies A and B, respectively, were
characterised by AUCs and slopes of the
volume profiles. Because the procedures had to
be discontinued at levels that varied between
individuals, especially during gastric disten-
sions, data sets from individuals were only ana-
lysed up to MDP+3 mm Hg, the highest com-
mon pressure step tolerated by all subjects
during all experimental conditions. As analysis
of MDPs assessed at various time points during
the study revealed that duodenal lipid de-
creased MDPs over time, all data were referred
to the initial MDP obtained at the beginning of
each study day, and data from the two
distensions were averaged.
Sensory responses
During infusions, AUCs (over 30 minutes) of
the VAS scores were used to compare the
eVects of the diVerent duodenal infusions on
symptoms. During distensions, AUCs for the
symptom profiles, obtained during the disten-
sion, during which symptoms were assessed at
each distension step, were calculated between
MDP and MDP+3 mm Hg.
CCK responses
During infusions, AUCs of plasma CCK levels
were calculated. During distensions, plasma
levels at the beginning and end of distensions
were compared. Data from the two distensions
were averaged.
STATISTICAL ANALYSIS
Data from study A were analysed by ANOVA.
If statistically significant group diVerences
were obtained (p<0.05), paired comparisons
were carried out using the Student’s t test. Data
from patients and healthy subjects obtained
during the 20% lipid infusion were compared
using an unpaired t test. Multiple comparisons
were accounted for by applying a Bonferroni
correction. Data from study B were analysed
using the Student’s t test. Data are presented as
mean (SEM).
350 Feinle,Meier, Otto, et al
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Results
STUDY A: DOSE-RESPONSE STUDY
Responses to duodenal infusions prior to gastric
distension
Gastric volume changes (fig 2, table 1).Duodenal
infusion of 10% and 20% lipid caused a com-
parable increase in intrabag volume and AUC
values: 20% lipid increased gastric volume
more in healthy subjects than in patients
(p<0.05).
Plasma CCK (fig 3). Baseline plasma levels
(pmol/l) did not diVer between study condi-
tions (saline 0.8 (0.3); 10% lipid 1.2 (0.3);
20% lipid 1.7 (0.7); p>0.05) or between
patients and healthy subjects (2.6 (0.8) pmol/l;
p>0.05). Duodenal infusion of both 10% and
20% lipid, but not of saline, raised plasma
CCK levels but only the increase during
infusion of 20% lipid reached statistical signifi-
cance. Plasma CCK levels were similar in
patients and healthy subjects during infusion of
20% lipid.
Symptom scores (fig 4A).There were no signifi-
cant diVerences between study conditions for
any of the symptoms assessed.
Responses to duodenal infusions with gastric
distension
Gastric pressure-volume relationship (table 1).
Infusion of both lipid emulsions caused a
greater increase in intrabag volumes at a given
pressure compared with saline (p<0.05). The
slope of the pressure-volume profiles increased
in patients with increasing amount of lipid
administered, indicating an increase in compli-
ance. In healthy subjects, 20% lipid caused a
greater increase in intragastric volumes during
gastric distension than in patients (p<0.05).
The slope of the pressure-volume profile
during infusion of 20% lipid was greater in
healthy subjects than in patients (p<0.05).
Plasma CCK (fig 3).Gastric distension did not
result in a further increase in plasma CCK lev-
els (pmol/l) in patients (saline pre 0.77 (0.22);
saline post 0.69 (0.21); 10% lipid pre 1.81
(0.69); 10% lipid post 2.03 (0.62); 20% lipid
pre 3.51 (0.61); 20% lipid post 3.10 (0.68)) or
healthy subjects (20% lipid pre 3.55 (0.71),
20% lipid post 3.97 (0.65)). Thus CCK
concentrations remained at levels comparable
with those found prior to distensions.
Symptom scores (fig 4B). During distensions,
symptoms of fullness, epigastric discomfort,
and nausea paralleled the increase in intragas-
tric pressure and showed a tendency to increase
with the rising dose of lipid administered, but
the diVerences were not statistically significant.
Symptoms experienced by patients during
infusion of 20% lipid were higher than in
healthy subjects, reaching statistical signifi-
cance for symptoms of fullness and pain
(p<0.05).
STUDY B: CCK-A RECEPTOR BLOCKADE STUDY
Responses to duodenal infusions prior to gastric
distension
Gastric volume changes (table 2). Intravenous
infusion of placebo or dexloxiglumide alone
did not aVect intragastric volumes (placebo 27
(4) ml; dexloxiglumide 28 (6) ml). Duodenal
infusion of 20% lipid resulted in an increase in
intragastric volume after placebo (186 (49) ml)
which was completely prevented by dexloxiglu-
mide (17 (9) ml). This diVerence was also
reflected in the AUC values.
Symptom scores (fig 5A). Infusion of dexloxiglu-
mide or placebo alone did not induce dyspep-
tic symptoms. Duodenal lipid, when given with
placebo, caused a slight but continuous in-
crease in symptoms while dexloxiglumide
completely abolished this eVect. The diVer-
ences between the two treatments reached sta-
tistical significance (p<0.05) for fullness
(AUCs: dexloxiglumide 52 (10); placebo 76
(17)), discomfort (dexloxiglumide 35 (11),
Figure 2 Gastric volume responses to duodenal infusion of
isotonic saline, or 10% or 20% lipid in patients with
functional dyspepsia (FD) and to infusion of 20% lipid in





























Table 1 Gastric responses to gastric distension and duodenal infusion of saline, or 10% or
20% lipid (study A)
Patients
Healthy subjects
Saline 10% lipid 20% lipid 20% lipid
Gastric volume changes during duodenal infusion
AUC (mm Hg*ml) 1222 (271) 3823 (413)†‡ 3954 (884)† 5786 (910)
Pressure-volume relationship during gastric distension
AUC (mm Hg*ml) 276 (40) 571 (106)† 736 (80)†‡ 1068 (148)
Slope (ml/mm Hg) 42 (8) 66 (10) 80 (16)†‡ 96 (9)
Data are mean (SEM), n=6.
Significantly diVerent from †saline, ‡healthy subjects, p<0.05.
AUC, area under the curve.
Figure 3 Plasma cholecystokinin (CCK) levels (baseline
levels normalised) obtained in response to duodenal infusion
of isotonic saline, or 10% or 20% lipid (n=6) in patients
with functional dyspepsia (FD) and healthy subjects (HS)
before and during gastric distensions. The value at t=20
minutes in healthy subjects is due to one outlier. D1,
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placebo 71 (19)) and nausea (dexloxiglumide
25 (8); placebo 68 (19)).
Responses to duodenal infusions with gastric
distension
Gastric pressure-volume relationship (table 2).
Intrabag volumes, expressed as AUC values,
and the slope of the pressure-volume profiles
were greater when lipid was given with
intravenous placebo than when given with dex-
loxiglumide (p<0.05), indicating a decrease in
gastric compliance during dexloxiglumide.
Symptom scores (fig 5B). During distensions,
dyspeptic symptoms developed with the in-
crease in intragastric pressure and were greater
during infusion of placebo than of dexloxiglu-
mide. The diVerences were statistically signifi-
cant (p<0.05) for fullness (AUCs: dexloxiglu-
mide 10 (2); placebo 14 (2)), bloating
(dexloxiglumide 6 (2); placebo 11 (3)), dis-
comfort (dexloxiglumide 8 (2); placebo 15
(4)), and nausea (dexloxiglumide 4 (2);
placebo 14 (4)).
Volume and pressure thresholds for discomfort.The
volumes at which discomfort occurred during
distensions were not diVerent between the pla-
cebo (V: 513 (48) ml) and dexloxiglumide (514
(47) ml) groups. However, maximally tolerated
pressures were higher during dexloxiglumide
(p: 20 (1) mm Hg) than during placebo (16 (1)
mm Hg; p<0.05), suggesting decreased sensi-
tivity to distension after dexloxiglumide.
Discussion
This study has demonstrated that gastro-
intestinal symptoms in patients with functional
dyspepsia induced by duodenal lipid infusion
and gastric distension can be relieved by
administration of the CCK-A receptor antago-
nist dexloxiglumide, indicating that CCK-A
receptor mechanisms are involved in the
generation of fat induced dyspeptic symptoms.
Dexloxiglumide abolished induction of dys-
peptic symptoms by lipid, reduced the severity
of symptoms in response to duodenal lipid
combined with gastric distension, and also
reduced the sensitivity to distension. Our
observations emphasise the involvement of fat
in the pathophysiology of functional dyspepsia.
Evidence for an association between lipid
induced dyspeptic symptoms and release of
endogenous CCK comes from the first part of
our study in which we investigated sympto-
matic and plasma CCK responses to two doses
of duodenal lipid. We found that both severity
of symptoms and plasma CCK levels were
increased in patients in a dose related fashion.
As plasma CCK levels in patients were not dif-
ferent from those in healthy subjects during
infusion of the 20% lipid emulsion, CCK
hypersecretion in patients can be excluded as
an underlying mechanism. Plasma CCK levels
comparable with those in healthy subjects more
likely indicate the existence of hypersensitivity
to CCK in patients. Accordingly, hypersensitiv-
ity to intravenously administered CCK has
been described in patients with functional dys-
pepsia.13 Although it is uncertain if CCK when
given intravenously adequately reproduces the
responses to endogenously released CCK and
induces gastrointestinal sensations and symp-
Figure 4 Scores for dyspeptic symptoms during duodenal infusion of isotonic saline, or
10% or 20% lipid in patients with functional dyspepsia (FD) and 20% lipid in healthy





















































































































Table 2 Gastric responses to gastric distension and
duodenal infusion of 20% lipid, with intravenous infusion





Gastric volume changes during duodenal infusion
AUC (mm Hg*ml) 4970 (982) 1120 (270)†
Pressure-volume relationship during gastric distension
AUC (mm Hg*ml) 565 (83) 209 (39)†
Slope (ml/mm Hg) 72 (11) 51 (7)†
Data are mean (SEM), n = 12.
†Significantly diVerent from placebo, p<0.05.
AUC, area under the curve.
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toms via the same mechanisms, data from both
studies indicate the possibility of such a hyper-
sensitivity reaction. The second line of evi-
dence is derived from the second part of our
study in which the selective CCK-A receptor
antagonist dexloxiglumide eliminated dyspep-
tic symptoms during lipid infusion alone and
significantly improved symptoms during lipid
infusion plus gastric distension in the patient
group. These results indicate that endogenous
CCK is involved in the pathophysiology of
functional dyspepsia via activation of CCK-A
receptors. CCK may act in a paracrine
fashion—that is, in close proximity to the site of
its release where the CCK concentration is very
high and this information can be conveyed to
the central nervous system via vagal aVerent
fibres. As this pathway is also involved in the
feedback inhibition of gastric tone and motility,
it is conceivable that gastric motor changes also
indirectly aVect symptoms. However, our
previous data suggest that symptom develop-
ment is not closely related to specific gastric
motor changes.4 CCK may activate CCK
receptors located in the mucosa and muscle
layers of the gastric wall. CCK-A receptor
immunoreactivity has recently been described
on rat gastric myenteric neurones and on fibres
in the mucosa and muscle.21 However, it is not
clear whether circulating CCK concentrations
are suYcient to activate gastric CCK receptors.
In addition, we cannot exclude the involvement
of a central eVect of CCK as we used a recep-
tor antagonist specific for CCK-A receptors
known to be located preferentially in the
periphery.
Activation of CCK-A receptors does not
fully explain dyspeptic symptoms induced dur-
ing gastric distension and duodenal lipid, as
blockade of these receptors improved but did
not entirely abolish symptoms. CCK-A recep-
tor antagonism during duodenal lipid infusion
and gastric distension may prevent sensitisa-
tion by CCK of a stomach that is already sen-
sitive to distension but not directly improve
mechanical hypersensitivity. Other CCK inde-
pendent mechanisms may also be involved.
Free fatty acids may cause transient irritation
of the intestinal mucosa22 23 leading to release of
neuromodulators such as serotonin which may
contribute to nausea, as has been shown previ-
ously.24 The irritant eVect of bile acids may also
cause dyspeptic symptoms.
Our finding that blockade of CCK-A recep-
tors improved dyspeptic symptoms during gas-
tric distension and duodenal lipid infusion has
potentially important implications for the
treatment of patients with functional dyspep-
sia. Preliminary studies in this group of
patients25 and in patients with irritable bowel
syndrome26 have shown a significant improve-
ment in symptoms during treatment with the
CCK-A antagonist loxiglumide. The availabil-
ity of orally administered CCK-A antagonists
may therefore oVer a new approach to the
treatment of functional dyspepsia. Further
studies in larger patient groups are required to
assess the potential therapeutic eVect of CCK
antagonists. However, it should also be pointed
out that patients with functional dyspepsia suf-
fer from symptoms in the fasted state, indicat-
ing that a trigger other than “postprandial”
stimuli, such as gastric distension and duode-
nal nutrients as used in our experimental
model, may be involved and require attention
in the treatment of this condition.
Gastric relaxation in response to duodenal
lipid infusion, reflected by an increase in intra-
bag volume, and compliance of the gastric wall
during gastric distensions were less in patients
than in healthy subjects. Impairment of gastric
accommodation in response to food has been
described previously and discussed as a con-
tributing factor to symptomatology.27–29 How-
ever, we found that dyspeptic symptoms were
Figure 5 Scores for dyspeptic symptoms during duodenal infusion of 20% lipid given with
intravenous placebo or dexloxiglumide in patients with functional dyspepsia (A) and when
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less intense and visceral sensitivity decreased,
despite the fact that gastric relaxation was
blocked and gastric compliance reduced by the
CCK-A antagonist. This observation is in con-
trast with what would be expected based on
previous findings and challenges whether
reduced gastric accommodation is a primary
factor in the pathophysiology of functional
dyspepsia or rather merely an epiphenomenon.
As we did not find any diVerences in gastric
compliance between the two lipid doses in
patients but observed a dose related eVect of
the lipid infusions on dyspeptic symptoms, we
postulate that small intestinal receptors are
involved in the pathophysiology of functional
dyspepsia. This conclusion is supported by our
previous studies4 7 8 12 demonstrating that acti-
vation of small intestinal receptors by increas-
ing luminal nutrient concentrations, particu-
larly fat, powerfully modulates visceral
sensitivity and the symptomatic response to
gastric distension. These previous data to-
gether with the present study emphasise the
importance of chemoreceptive modulation of
visceral sensitivity and symptomatology.
Despite significantly enhancing symptoms,
gastric distension did not increase plasma
CCK levels further in patients or healthy
subjects. This finding is in contrast with data
from another study in humans30 in which an
81% increase in plasma CCK was observed
after fundic distension. In contrast, antral
distension does not appear to cause CCK
secretion.30 31 The lack of eVect of fundic
distension in our own study may be due to the
fact that duodenal lipid already induced
marked (100–400%) increases in plasma CCK
levels prior to distension and therefore no
additional CCK release may have occurred
during distensions. However, gastric distension
alone did not cause an increase in plasma CCK
during duodenal infusion of the saline control
solution. Hence our data do not support the
notion that gastric distension is a stimulus for
CCK release.
Anxiety and hypervigilance may also have an
influence on symptom severity and gastro-
intestinal perception.32 However, we did not
find any diVerences in the data of patients par-
ticipating in studies A and B. Both symptom
severity and perception could have been
increased in study B, due to expectation and
hypervigilance, or reduced because patients
had become familiar with the procedures dur-
ing study A; neither was the case. We chose
ramp distensions in our protocol as this disten-
sion mode most closely reflects gastric disten-
sion during food intake. In addition, it has been
demonstrated recently in the oesophagus that
the perception of stimuli is enhanced with an
irregular stimulus presentation, perhaps as a
result of anxiety and fear of sudden discom-
fort.19
In summary, our data demonstrated that the
eVects of duodenal lipid on dyspeptic symp-
toms during gastric distension increased with
the dose of lipid administered and were paral-
leled by increases in plasma CCK levels.
CCK-A receptor blockade by dexloxiglumide
markedly diminished the response, indicating
that CCK-A dependent mechanisms are in-
volved in the pathophysiology of functional
dyspepsia. Our findings may provide a ration-
ale for the treatment of functionally dyspeptic
patients with CCK-A antagonists.
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